Hindawi Publishing Corporation Journal of Ophthalmology Volume 2015, Article ID 515193, 1 page http://dx.doi.org/10.1155/2015/515193

Editorial Advances in Retinal Therapeutics Petros E. Carvounis,1 Thomas A. Albini,2 Andrew J. Barkmeier,3 and Miltiadis Tsilimbaris4 1

Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA Bascom Palmer Eye Institute, Miami, FL 33136, USA 3 Department of Ophthalmology, Mayo Clinic, Rochester, MN 55905, USA 4 Department of Ophthalmology, University of Crete Medical School, 71 003 Heraklion, Greece 2

Correspondence should be addressed to Petros E. Carvounis; [email protected] Received 1 December 2014; Accepted 1 December 2014 Copyright © 2015 Petros E. Carvounis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In recent years there have been monumental and exciting advances in the treatment of retinal disease which made a special issue on advances in retinal therapeutics relevant and interesting. Indeed, in this issue there are 11 papers reporting either original basic or clinical research findings or reviewing the literature and reporting recent developments. The papers in this issue are on a wide range of topics. J. He et al. present original basic research in elucidating the effects of VEGF receptor 1 blockade on diabetic retinopathy while M. L. Perepechaeva et al. present original basic research identifying a potential novel target for the treatment of agerelated macular degeneration in a rodent animal model of the disease. O. Chrapek et al. present original clinical research identifying occult CNVM and lesion size less than 5 disc diameters as baseline characteristics predicting inactivity after 3 injections of an intravitreous anti-VEGF agent (ranibizumab) for neovascular age-related macular degeneration (nARMD). S. M. Prea et al. review endogenous inhibitors of nARMD as well as the principles of gene therapy that could use such inhibitors to treat nARMD clinically. There are 2 papers discussing advances in retinal laser treatment—one by Y. G. Park et al. discussing developments on laser photocoagulation for diabetic macular edema and another by K. Inagaki et al. discussing micropulse laser for persistent macular edema from branch retinal vein occlusion in eyes which includes eyes with good visual acuity at baseline. Two additional papers address vitreoretinal surgery topics: one by Dr. C. Pournaras et al. that reports on the outcomes of repair of recurrent retinal detachment, including presenting visual outcomes which are not uncommonly omitted in prior publications and the other paper by A. Garc´ıa-Layana et al. that

reviews the current treatment of vitreomacular traction and macular hole. The paper by M. Harrell and P. E. Carvounis is an up-to-date evidence-based review of the treatments of toxoplasma retinochoroiditis which takes into account evidence published within the last 2 years when the previous evidencebased review was published. Finally, the paper by M. Cabrera et al. reviews the 3 sustained-release corticosteroids available for the treatment of retinal disease. The 54 authors and coauthors should be commended for the quality of their manuscripts; the science as well as the writing is of high caliber. It is our belief that the readership of the Journal of Ophthalmology will enjoy reading the papers in this special issue as much as we did. Petros E. Carvounis Thomas A. Albini Andrew J. Barkmeier Miltiadis Tsilimbaris

Advances in retinal therapeutics.

Advances in retinal therapeutics. - PDF Download Free
432KB Sizes 1 Downloads 7 Views

Recommend Documents


Microbiome therapeutics - Advances and challenges.
The microbial community that lives on and in the human body exerts a major impact on human health, from metabolism to immunity. In order to leverage the close associations between microbes and their host, development of therapeutics targeting the mic

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.
Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC). With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and effective targeted therapies, therapeu

Advances in preparation and characterization of chitosan nanoparticles for therapeutics.
Polymers have been largely explored for the preparation of nanoparticles due to ease of preparation and modification, large gene/drug loading capacity, and biocompatibility. Various methods have been adapted for the preparation and characterization o

Advances in retinal ganglion cell imaging.
Glaucoma is one of the leading causes of blindness worldwide and will affect 79.6 million people worldwide by 2020. It is caused by the progressive loss of retinal ganglion cells (RGCs), predominantly via apoptosis, within the retinal nerve fibre lay

Bisphosphonates: therapeutics potential and recent advances in drug delivery.
Bisphosphonates (BPs) are widely used for prevention and treatment of osteoporosis. BPs are known as gold standard for osteoporosis (OP) treatment due to their positive results in clinical studies. But some serious side effects are associated with BP

Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease.
The functional significance of cannabinoids in ocular physiology and disease has been reported some decades ago. In the early 1970s, subjects who smoked Cannabis sativa developed lower intraocular pressure (IOP). This led to the isolation of phytocan

Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics.
A main challenge in realizing the full potential of nucleic acid therapeutics is efficient delivery of them into targeted tissues and cells. N-acetylgalactosamine (GalNAc) is a well-defined liver-targeted moiety benefiting from its high affinity with

Dendrimer advances for the central nervous system delivery of therapeutics.
The effectiveness of noninvasive treatment for central nervous system (CNS) diseases is generally limited by the poor access of therapeutic agents into the CNS. Most CNS drugs cannot permeate into the brain parenchyma because of the blood-brain barri